InforSense Suite Streamlines Analysis of Genomic, Clinical and Image Data

Guildford, UK, and Burlington, Mass. – IDBS, the leading worldwide provider of data management and analytics solutions to R&D and healthcare organizations, today announced that Barts and The London NHS Trust, one of Britain’s leading healthcare providers, has selected IDBS as its translational research informatics platform for data analysis and visualization to support cardiovascular biomedical research. Barts, founded in 1123, and the Royal London, founded in 1740, are home to the country’s first school of medicine and dentistry. Barts will use IDBS’ InforSense Suite to better understand the causes of cardiovascular disease and develop better treatment therapies.

The InforSense Suite is a secure web-based data integration, analysis, and visualization system that enables researchers to navigate and understand large amounts of data quickly. It is the leading solution for combining genetic data such as genome-wide association studies with clinical data such as patient medical history and image data such as CT or MRI scans. Researchers are able to quickly and intuitively select subject cohorts for translational research studies using ClinicalSense, part of the InforSense Suite, and then link seamlessly to data analysis and annotation.

“The Cardiovascular Biomedical Research Unit at Barts aims to understand the basic underlying pathogenic mechanisms associated with vascular diseases, e.g., atherosclerosis, hypertension and diabetes,” said Professor Anthony Mathur, Consultant Cardiologist at Barts and The London NHS Trust. “After a lengthy evaluation of all the organizations in this space, IDBS came out top of our procurement analysis.”

“We are extremely pleased to be working with the world-class researchers at Barts and The London NHS Trust,” said Neil Kipling, founder and CEO of IDBS. “Our work with Barts and The London provides further validation of our unique technology for translational research, which is an area of strategic importance to healthcare providers and pharmaceutical organizations. IDBS is a global leader in this exciting new field, providing the major stakeholders with enabling technologies and expertise.”

The project was made possible through a £5.45 million grant from the National Institute for Health Research (NIHR) to Barts and The London’s new Cardiovascular Bio-Medical Research Unit. This included funding for the bio-informatics system in line with the NIHR’s goal to support outstanding individuals, working in world class facilities, to conduct leading edge research focused on the needs of patients and the public.

About Barts and The London NHS Trust

Barts and The London NHS Trust is one of Britain’s leading healthcare providers. Our world-renowned hospitals – St. Bartholomew’s in the City, The Royal London in Whitechapel and The London Chest in Bethnal Green founded in 1848 – have made, and continue to make, an outstanding contribution to modern medicine.

Together, we employ 7,800 staff, including some of Britain’s leading specialists, and we care for over 700,000 patients every year. Our full portfolio of specialist services includes leading cancer, cardiac, gastroenterology, trauma and emergency care centres, as well as one of Britain’s biggest children’s hospitals. Patients come from all over the UK benefit from our expertise, although mostly we care for the two million people living locally in east London. We serve Europe’s most diverse communities – from the wealthy financial districts of the City and Canary Wharf to some of Britain’s most deprived areas.

With the opening of the Barts Cancer Centre, attention has now turned to the completion of the new Royal London Hospital. The internal fit-out continues apace, and the new hospital remains on time and on budget to welcome its first patients in 2010. During 2010 preliminary work will begin on the second phase of the redevelopment of Barts which will see the opening of a specialist cardiac centre in 2014.

About IDBS

IDBS is a unique, global supplier of innovative data management and analytics solutions, which increase efficiency, reduce costs and improve business and scientific productivity of R&D organizations worldwide. Organizations such as Pfizer, GSK, Celera, MedImmune, Dana-Farber, and Roche employ IDBS solutions as an integral part of their strategy to address the increasing pressures placed upon them by the need for the secure, compliant capture, integration and analysis of complex research data. IDBS is clearly differentiated from other software providers by its unique combination of deep domain knowledge and its ability to rapidly provide integrated business process and robust data analytics solutions along the entire R&D value chain. IDBS solutions secure organizations’ valuable R&D data assets and enable rapid decision-making through effective integration and analysis. They also support the protection of Intellectual Property (IP) and the requirements for data quality demanded under Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards.

IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China.